MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN

HER2-overexpressing breast cancers are characterized by frequent distant metastasis and often develop resistance after short-term effective treatment with the monoclonal antibody drug, trastuzumab. Here, we found that the oncogenic miRNA, miR-221, inhibited apoptosis, induced trastuzumab resistance and promoted metastasis of HER2-positive breast cancers. The tumor suppressor PTEN was identified as a miR-221 target; overexpression of PTEN abrogated the aforementioned miR-221-induced malignant phenotypes of the cells. These findings indicate that miR-221 may promote trastuzumab resistance and metastasis of HER2-positive breast cancers by targeting PTEN, suggesting its role as a potential biomarker for progression and poor prognosis, and as a novel target for trastuzumab-combined treatment of breast cancers. [BMB Reports 2014; 47(5): 268-273].

[1]  E. Winer,et al.  Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma , 2003, Cancer.

[2]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Thompson,et al.  Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complex , 2011, Molecular Cancer.

[4]  Jing Liu,et al.  MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN , 2012, Molecular and Cellular Biochemistry.

[5]  B. White,et al.  Involvement of microRNAs in breast cancer. , 2008, Seminars in reproductive medicine.

[6]  Meng Li,et al.  MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways , 2011, Oncogene.

[7]  S. Eccles.  The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[8]  Z. Hall.  Cancer , 1906, The Hospital.

[9]  S. Ménard,et al.  HER2 as a Prognostic Factor in Breast Cancer , 2001, Oncology.

[10]  M. Owens,et al.  HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.

[11]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[12]  Hansjuerg Alder,et al.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. , 2009, Cancer cell.

[13]  J. Bergh,et al.  A Population-based Study on the First Forty-Eight Breast Cancer Patients Receiving Trastuzumab (Herceptin®) on a Named Patient Basis in Sweden , 2002, Acta oncologica.

[14]  P. Pu,et al.  MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN , 2010, BMC Cancer.

[15]  Giovanni Vanni Frajese,et al.  miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1* , 2007, Journal of Biological Chemistry.

[16]  Mauro Biffoni,et al.  The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. , 2008, Cancer research.

[17]  P. Dennis,et al.  PTEN loss in the continuum of common cancers, rare syndromes and mouse models , 2011, Nature Reviews Cancer.

[18]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Carlos L Arteaga,et al.  Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer , 2011, Breast Cancer Research.

[20]  Wei Chen,et al.  Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. , 2011, Cancer research.

[21]  X. Mao,et al.  Upregulation of miR‐153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer , 2013, The Prostate.

[22]  Lajos Pusztai,et al.  Targeted Therapy in Breast Cancer , 2004, Molecular & Cellular Proteomics.

[23]  Yangde Zhang,et al.  Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells , 2011, Molecular and Cellular Biochemistry.

[24]  M. Duffy,et al.  Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib , 2010, Molecular Cancer Therapeutics.

[25]  Massimo Cristofanilli,et al.  Molecular prognostic factors for breast cancer metastasis and survival. , 2002, Seminars in radiation oncology.

[26]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[27]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.